crizotinib for alk-rearranged nsclc
Published 8 years ago • 1.5K plays • Length 7:02Download video MP4
Download video MP3
Similar videos
-
4:28
changing the treatment paradigm for alk-rearranged nsclc
-
8:16
alta ii trial of brigatinib in alk-rearranged nsclc
-
1:27
dr. ou on the use of crizotinib in patients with ros1-rearranged nsclc
-
3:13
available therapies for alk-rearranged nsclc
-
6:37
ascend-4: upfront ceritinib in alk-rearranged nsclc
-
4:10
crizotinib resistance in alk nsclc
-
1:23
ascend-1 and ascend-2: ceritinib for alk-rearranged nsclc and baseline brain metastases
-
0:44
dr. mark kris discusses crizotinib for patients with alk-positive lung cancer
-
4:38
patterns of progression on crizotinib for alk nsclc
-
4:38
alta ii: brigatinib in crizotinib-resistant alk nsclc
-
9:33
second-line brigatinib for alk/ros1-rearranged nsclc
-
0:56
crizotinib for first line treatment of alk or ros1 rearrangements
-
1:22
dr. crinò on crizotinib in alk nsclc
-
2:29
dr. ross camidge discusses crizotinib in ros1 rearranged nsclc
-
7:03
sequencing therapies for alk-rearranged nsclc
-
1:09
dr. camidge on crizotinib as a ros1 inhibitor in nsclc
-
3:08
available treatment options for relapsed alk-rearranged nsclc
-
5:19
ascend-5: ceritinib for alk positive nsclc previously treated with crizotinib
-
4:43
upfront therapy for alk/ros1-rearranged nsclc